Analyst Price Targets — KLRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 16, 2026 8:54 am | — | Morgan Stanley | $14.00 | $5.87 | TheFly | Kalaris Therapeutics initiated with an Overweight at Morgan Stanley |
| March 9, 2026 2:57 pm | Chris Raymond | Raymond James | $23.00 | $9.51 | StreetInsider | Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS) |
| December 23, 2025 9:31 am | — | Chardan Capital | $19.00 | $10.06 | TheFly | Kalaris Therapeutics initiated with a Buy at Chardan |
| July 23, 2025 8:52 am | Biren Amin | Piper Sandler | $3.00 | $2.57 | TheFly | Kalaris Therapeutics assumed with a Neutral at Piper Sandler |
Latest News for KLRS
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027
Kalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Buys 479,847 Shares of Stock
Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) Director Srinivas Akkaraju purchased 479,847 shares of the business's stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $10.42 per share, with a total value of $5,000,005.74. Following the completion of the transaction, the director owned 1,979,847 shares of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KLRS.
U.S. House Trading
No House trades found for KLRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.